A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

NCT04564092 | Completed Phase 1 Results

• 1 other identifier: GE-001-023
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase 1, single-centre, single-group, nonrandomized, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I) injection in Chinese Healthy Volunteers.

Conditions

Healthy Subjects (HS)

Keywords

Single photon emission computed tomography (SPECT); Healthy Volunteer (HV)

Outcome Measures

Primary Outcomes (26)

• Number of Participants With Adverse Events (AEs)

  An AE was defined as any untoward medical occurrence in participants or clinical investigation participant which did not necessarily have to have been related to the investigational medical product (IMP). AEs were recorded from time of informed consent through the follow-up visit at 2 weeks (±2 days) after IMP administration.

  Baseline up to 2 weeks after IMP administration (i.e., up to 16 days)

• Change From Baseline in Tolerability Questionnaire Score at Approximately 15 Minutes, 1, 4, 24, 48 Hours After DaTSCAN™ Ioflupane (123I) Injection as Measured by VAS (Visual Analogue Scale)

  Tolerability questionnaire evaluated participants mood, pain at injection site, itchiness of injection site, loss of function at injection site and quality of sleep using 100 millimeter (mm) VAS. VAS is a continuous scale comprised of a horizontal line, usually 100 mm in length, where "0" stands for bad, and 100 mm stands for good. Higher score indicated better health outcomes.

  1 hour before injection (baseline), and at approximately 15 minutes, 1, 4, 24, 48 hours after DaTSCAN™ ioflupane (123I) injection

• Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings Pre-specified Timepoints

  Physical examination included recording an assessment for the presence of abnormalities of the following: general appearance, skin, lungs, cardiovascular system, back and spine, abdomen, extremities, lymph nodes, and neurological exam. Clinical significance was determined by investigator.

  Baseline, 4 hours after injection and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Hematology Parameters at Pre-specified Timepoints

  Change from baseline in activated partial thromboplastin time, prothrombin time, thrombin time were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Hematology Parameter-C Reactive Protein at Pre-specified Timepoints

  Change from baseline in C reactive protein were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Hematology Parameter-Hematocrit at Pre-specified Timepoints

  Change from baseline in hematocrit were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Hematology Parameter-Erythrocytes at Pre-specified Timepoints

  Change from baseline in erythrocytes were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Hematology Parameters- Leukocytes, Platelets at Pre-specified Timepoints

  Change from baseline in leukocytes, platelets timepoints were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Hematology Parameters- Fibrinogen, Hemoglobin at Pre-specified Timepoints

  Change from baseline in fibrinogen, hemoglobin were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Serum Chemistry Parameters- Albumin, Protein at Pre-specified Timepoints

  Change from baseline in albumin, protein were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Serum Chemistry Parameters- Thyroxine, Free and Triiodothyronine, Free at Pre-specified Timepoints

  Change from baseline in thyroxine, free and triiodothyronine, free were reported.

  Baseline, and at 48 hours after DaTSCAN™ ioflupane (123I) injection

• Change From Baseline in Serum Chemistry Parameters at Pre-specified Timepoints

  Change from baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatine kinase, gamma glutamyl transferase, lactate dehydrogenase were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Serum Chemistry Parameters- Thyroxine and Triiodothyronine at Pre-specified Timepoints

  Change from baseline in thyroxine and triiodothyronine were reported.

  Baseline, and at 48 hours after DaTSCAN™ ioflupane (123I) injection

• Change From Baseline in Serum Chemistry Parameters- Bilirubin, Creatinine, Direct Bilirubin, and Urate at Pre-specified Timepoints

  Change from baseline in bilirubin, creatinine, direct bilirubin, and urate were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Serum Chemistry Parameters- Bicarbonate, Calcium, Chloride, Glucose, Phosphate, Potassium, Sodium, Urea Nitrogen at Pre-specified Timepoints

  Change from baseline in bicarbonate, calcium, chloride, glucose, phosphate, potassium, sodium, urea nitrogen were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Serum Chemistry Parameters- Thyrotropin at Pre-specified Timepoints

  Change from baseline in thyrotropin were reported.

  Baseline, and at 48 hours after DaTSCAN™ ioflupane (123I) injection

• Change From Baseline in Serum Chemistry Parameters- Amylase at Pre-specified Timepoints

  Change from baseline in amylase were reported.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Number of Participants With Clinically Significant Abnormal Urinalysis Parameters - pH and Specific Gravity at Pre-specified Timepoints

  Number of participants with clinically significant abnormal pH and specific gravity were reported. Clinical significance was determined by investigator.

  Baseline, and at approximately 3 hours, 48 hours, and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Number of Participants Who Reported Abnormal Injection Site Monitoring Findings at Pre-specified Timepoints

  Any radiopharmaceutical extravasation, bleeding, hematoma, redness, infection, or other findings were considered as abnormal findings.

  Baseline, up to 4 hours after DaTSCAN™ ioflupane (123I) injection

• Change From Baseline in Vital Sign-Systolic Blood Pressure at Pre-specified Timepoints

  Change from baseline in systolic blood pressure were reported.

  Baseline, 10, 20, 30 minutes and 1, 2, 4, 24, 48 hours and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Vital Sign-Diastolic Blood Pressure at Pre-specified Timepoints

  Change from baseline in diastolic blood pressure were reported.

  Baseline, 10, 20, 30 minutes and 1, 2, 4, 24, 48 hours and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Vital Sign-Heart Rate at Pre-specified Timepoints

  Change from baseline in heart rate were reported.

  Baseline, 10, 20, 30 minutes and 1, 2, 4, 24, 48 hours and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Vital Sign-Temperature at Pre-specified Timepoints

  Change from baseline in temperature were reported.

  Baseline, 10, 20, 30 minutes and 1, 2, 4, 24, 48 hours and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Vital Sign-Respiratory Rate at Pre-specified Timepoints

  Change from baseline in respiratory rate were reported.

  Baseline, 10, 20, 30 minutes and 1, 2, 4, 24, 48 hours and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Oxygen Saturation at Pre-specified Timepoints

  Change from baseline in oxygen saturation were reported.

  Baseline, 10, 20, 30 minutes and 1, 2, 4, 24, 48 hours and 2 weeks after DaTSCAN™ ioflupane (123I) injection (i.e., up to 16 days)

• Change From Baseline in Electrocardiogram (ECG) Findings at Pre-specified Timepoints

  Change from baseline in PR interval, QRS interval, QT interval, QTC interval, RR interval, QTCF interval, QTCB interval were reported.

  Baseline, 2 and 5 hours after DaTSCAN™ ioflupane (123I) injection

Secondary Outcomes (6)

• Biodistribution Measured by Decay Corrected Percentage Injected Activity (%IA) in Blood (Plasma and Whole Blood)

  Pre-dose, 5, 15, 30 minutes and 1, 2, 3, 4, 5, 24, and 48 hours after DaTSCAN™ ioflupane (123I) injection

• Biodistribution Measured by Decay Corrected Percentage Injected Activity (%IA) in Whole Body Image

  10 minutes and 1, 2, 4, 5, 24, and 48 hours after DaTSCAN™ ioflupane (123I) injection

• Biodistribution by Source Regions Measured by Decay Corrected Normalized Cumulative Activity

  Up to 48 hours after DaTSCAN™ ioflupane (123I) injection

• Biodistribution as Measured by Decay-corrected Cumulative 123I Activity Concentration in Excreted Urine

  10 minutes and 1, 2, 3, 4, 5, 5 to 24, and 24 to 48 hours after DaTSCAN™ ioflupane (123I) injection

• Normalized Organ Absorbed Doses as Measured by Radiation Dosimetry

  Up to 48 hours after DaTSCAN™ ioflupane (123I) injection

Study Arms (1)

DaTSCAN™ ioflupane (123I) injection

EXPERIMENTAL

Participants will receive a single intravenous (IV) injection of DaTSCAN™ ioflupane (123I) injection into an arm vein, followed by planar whole-body imaging at prespecified time points over a period of 48 hours after administration. Brain SPECT imaging will be acquired at 3 and 6 hours after administration.

Drug: DaTSCAN™ Ioflupane (123I) Injection

Interventions

DaTSCAN™ Ioflupane (123I) Injection DRUG

Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.

Also known as: Ioflupane (123I)

DaTSCAN™ ioflupane (123I) injection

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Chinese male or female who has agreed to sign and date the written informed consent form
• Age 18-70 years
• Body mass index (BMI) of 18-30 kg/m\^2
• General good state of health as judged by a qualified physician after completing physical examination
• Fit, co-operative, and able to provide consent

You may not qualify if:

• Sensitivity to DaTSCAN™ ioflupane (123I) injection or any of its ingredients
• A history of motor disturbances
• A history of pulmonary, cardiovascular, neurological, renal or hepatic, hormonal or coagulation disorders or hyperthyroidism
• A history of drug, alcohol, or solvent abuse
• The subject has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening
• Radionuclide injection within a minimum of 5 radioactive half-lives prior to screening
• Use of any medication (except paracetamol \[acetaminophen\] or oral contraceptive), including traditional Chinese medicine, within 2 weeks prior to the imaging visit
• Classification as a radiation worker
• Women of child-bearing potential not accepting a highly effective method of birth control (A woman is considered of child-bearing potential, i.e., fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Postmenopausal is defined as 12 months with no menses without an alternative medical cause, in International Council on Harmonisation (ICH) M3 (R2); A highly effective method of birth control is defined as one which results in a low failure rate (i.e., less than 1 % per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomised partner, in ICH M3 (R2).
• Pregnant or lactating women

Sponsors & Collaborators

• GE Healthcare: lead
• PPD Development, LP: collaborator

Study Sites (1)

Rujin hospital, affiliated to Shanghai Jiaotong University, School of Medicine

Huangpu, Shanghai Municipality, 200025, China

Location

Related Publications (1)

• Zhang M, Wang Y, Wang J, Li X, Li B. Safety, biodistribution and radiation dosimetry of [123I]ioflupane in healthy Chinese volunteers. EJNMMI Res. 2023 Apr 7;13(1):30. doi: 10.1186/s13550-023-00978-3.

  PMID: 37029298 DERIVED

MeSH Terms

Interventions

Iodine-123; Injections; ioflupane

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Results Point of Contact

• Title: Yongqing Tang, MD PhD
• Organization: GE Healthcare

Yongqing.Tang@ge.com

189-1820-3986

Study Officials

• Biao LI

  Rujin Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 30, 2020
• First Posted: September 25, 2020
• Study Start: May 13, 2021
• Primary Completion: September 4, 2021
• Study Completion: September 4, 2021
• Last Updated: August 2, 2023
• Results First Posted: August 2, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)